Second Round Polio Vaccination Begins in Malawi

**Lilongwe – **Malawi launches the second of four rounds of vaccination campaigns against wild poliovirus type 1 today. More than eleven (11) million doses will be administered to more than 2.9 million children under 5 years in the four-round vaccination drive in Malawi after the country declared an outbreak on 17 February—the first such case in the country in 30 years, and the first in Africa since the region was certified free of indigenous wild poliovirus in 2020.

The second phase of the campaign, which begins this week, targets children under 5 in Malawi, as well as its neighbors, Mozambique, Tanzania and Zambia. Two subsequent rounds are set for June and July, with the first having already taken place in April. Cumulatively, these aim to reach over 23 million children with more than 80 million doses of the bivalent Oral Polio Vaccine recommended by World Health Organization (WHO) for wild poliovirus (type 1).

Mass vaccinations, or supplementary vaccinations, aim to interrupt the circulation of poliovirus by immunizing every child under 5 years with oral polio vaccine regardless of previous immunization status. The objective is to reach children who are either not immunized, or only partially protected, and to boost immunity in those who have been immunized. Supplementary immunization is intended to complement—not replace—routine immunization.

“It’s a nationwide campaign,” said Janet Kayita, WHO Country Representative for Malawi. “It’s targeting all under-5s in Malawi and it’s really a race to get ahead of the polio outbreak and this is really important for Malawi but also important for the region.”

“Polio is a highly infectious and an untreatable disease that can result in permanent paralysis. In support of Malawi and it neighbours, we are acting fast to halt this outbreak and extinguish the threat through effective vaccinations,” said Janet Kayita, WHO Country Representative for Malawi. “The African region has already defeated wild poliovirus due to a monumental effort by countries. We have the know-how and are tirelessly working to ensure that every child lives and thrives in a continent free of polio.”

The African region was declared and certified as free of indigenous wild polio in August 2020 after eliminating all forms of wild poliovirus. The region’s certification as wild polio-free remains unchanged. Laboratory analysis linked the strain detected in Malawi to the one circulating in Pakistan’s Sindh Province in 2019.

WHO has been supporting the country to reinforce response measures including disease surveillance, risk assessment and preparations for the vaccination campaigns. A surge team from WHO is working with country-based counterparts, partner organizations and the government to end the outbreak. The WHO team is part of a broader multi-partner Global Polio Eradication Initiative support to the country.

Malawi has also now set up environmental surveillance for polioviruses in 11 sites across four cities. The sites are in Lilongwe District that encompasses the capital Lilongwe where the initial, and so far, only case, was detected. Other sites are in Blantyre, Mzuzu and Zomba cities. Teams are collecting samples from the environment and sending them for analysis to laboratories while active surveillance is also underway in health facilities and in communities.

In preparation for the vaccination drives, trained surge teams of national officers have been deployed at district level to facilitate the campaign and ensure that all eligible children are vaccinated. Maintenance and repair of cold chain facilities are also ongoing.

Polio is a viral disease with no cure. It invades the nervous system and can cause total paralysis within hours, particularly among children under 5 years. The virus is transmitted from person to person mainly through contamination by faecal matter or, less frequently, through contaminated water or food, and multiplies in the intestine. While there is no cure for polio, the disease can be prevented through administration of a safe, simple and effective vaccine.

Source: World Health Organization

Drop in Vaccines Exposes Latin American Children to Disease, Report Shows

One in four children in Latin America and the Caribbean does not have vaccine protection against three potentially deadly diseases, a U.N. report said Monday, warning of plummeting inoculation rates.

While 90% of children in the region in 2015 had received the vaccine for diphtheria, tetanus and whooping cough (DTP3), by 2020 coverage had dropped to three-quarters, according to the U.N. Children’s Fund (UNICEF) and the Pan American Health Organization (PAHO), a regional office of the World Health Organization.

This means that some 2.5 million children were not fully protected — and 1.5 million of them have not had even one dose in the three-shot regimen.

Globally, according to WHO, 17.1 million infants did not receive an initial dose of the DTP3 vaccine in 2020, and another 5.6 million were only partially jabbed.

Outbreaks of preventable diseases “have already occurred” in Latin America and the Caribbean, the agencies said.

In 2013, only five people in the region contracted diphtheria — a bacterial disease that can cause breathing difficulties, heart failure and potentially death.

Five years later, the number was nearly 900.

There has also been a rise in cases of measles — another disease that can be prevented with inoculation — from nearly 500 cases in 2013 to more than 23,000 in 2019, said the statement.

“The decline in vaccination rates in the region is alarming,” said UNICEF regional director Jean Gough.

The reasons were multifold.

“The context in the region has changed in the last five years. Governments have focused their attention on other emerging public health issues such as Zika, chikungunya and more recently COVID-19,” UNICEF neonatal expert Ralph Midy told AFP.

“The existence of migrant populations that are difficult to locate and do not always have access to regular health services, in addition to people living in isolated or hard-to-reach areas, also hinders the vaccination process,” Midy said.

The downward trend started even before the COVID-19 epidemic, which worsened the situation by interrupting primary health care services and causing some people to avoid clinics and hospitals for fear of the virus.

“As countries recover from the pandemic, immediate actions are needed to prevent (vaccine) coverage rates from further dropping, because the re-emergence of disease outbreaks poses a serious risk to all of society,” said Gough.

Source: Voice of America

US Regulator Approves Gilead’s COVID Drug for Young Children

The U.S. drug regulator on Monday granted the first full approval for treating COVID-19 in children age 28 days and older to Gilead Sciences Inc.’s drug remdesivir.

The move comes months after the agency expanded the drug’s emergency use authorization to include children younger than 12 and weighing at least 3.5 kilograms.

The Food and Drug Administration’s (FDA) decision makes the drug the first approved COVID-19 treatment for children under 12 years old, the agency said.

The approval is applicable to children who are hospitalized or have mild-to-moderate disease and are at high risk of severe COVID-19.

Source: Voice of America